Albano Domenico, Bonacina Mattia, Durmo Rexhep, Bertagna Francesco, Giubbini Raffaele
Nuclear Medicine, University of Brescia, Brescia, Italy.
Nuclear Medicine, Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy.
Endocrine. 2020 Apr;68(1):124-131. doi: 10.1007/s12020-019-02148-9. Epub 2019 Nov 29.
The aim of our study was to compare the efficacy of thyroid remnant ablation using low (1.1 GBq) and intermediate-high radioiodine (RAI) activity (1.85-3.7 GBq) in low-risk differentiated thyroid carcinoma (DTC) and to evaluate the staging role of the whole body scan (WBS) in detection extrathyroidal disease.
We retrospectively included 277 patients who underwent total thyroidectomy and RAI for low-risk DTC and divided them in two groups according to RAI activity at ablation: group 1 (n = 174) treated with low activity (1.1 GBq), and group 2 (n = 103) with intermediate-high activity (1.85-3.7 GBq). To evaluate the successful ablation rate, the WBS 1 year after RAI was visually interpreted using a three-point scale: score 0 in case of absence of visible RAI uptake in thyroid bed; score 1 in presence of faint uptake in the thyroid bed; and score 2 in case of significant RAI uptake in thyroid bed.
The success ablation rate was significantly higher in group 2 than group 1 (p < 0.001) with the presence of a positive WBS (score 1-2) in 65% low-activity group and 33% in intermediate-high group. Considering response to therapy categories, excellent response rate was significantly higher in group 2 (p = 0.020), while indeterminate response was higher in group 1 (p value = 0.005). Post RAI imaging revealed extrathyroidal uptake in 27 cases: 17 laterocervical nodal and 10 distant metastases. In both groups similar detection rate of nodal and distant metastases were recognized without any statistical difference.
The ablation rate with intermediate-high RAI activity (1.85-3.7 GBq) was better than with a low activity (1.1 GBq). First WBS may help to recognize nodal and distant metastases in about 10% of cases changing clinical stage and subsequent management.
本研究旨在比较低剂量(1.1GBq)和中高剂量放射性碘(RAI)(1.85 - 3.7GBq)用于低风险分化型甲状腺癌(DTC)甲状腺残余组织消融的疗效,并评估全身扫描(WBS)在检测甲状腺外疾病中的分期作用。
我们回顾性纳入了277例行全甲状腺切除术及RAI治疗的低风险DTC患者,并根据消融时的RAI剂量将他们分为两组:第1组(n = 174)接受低剂量(1.1GBq)治疗,第2组(n = 103)接受中高剂量(1.85 - 3.7GBq)治疗。为评估成功消融率,在RAI治疗1年后对WBS进行视觉解读,采用三点量表:甲状腺床无可见RAI摄取为0分;甲状腺床有微弱摄取为1分;甲状腺床有明显RAI摄取为2分。
第2组的成功消融率显著高于第1组(p < 0.001),低剂量组65%出现阳性WBS(1 - 2分),中高剂量组为33%。考虑治疗反应类别,第2组的优秀反应率显著更高(p = 0.020),而第1组的不确定反应更高(p值 = 0.005)。RAI治疗后成像显示27例有甲状腺外摄取:17例为颈侧淋巴结转移,10例为远处转移。两组在淋巴结和远处转移的检测率相似,无统计学差异。
中高剂量RAI(1.85 - 3.7GBq)的消融率优于低剂量(1.1GBq)。首次WBS可能有助于在约10%的病例中识别淋巴结和远处转移,从而改变临床分期及后续治疗方案。